Evaluation of Radiolabeled Girentuximab In Vitro and In Vivo

Girentuximab (cG250) targets carbonic anhydrase IX (CAIX), a protein which is expressed on the surface of most renal cancer cells (RCCs). cG250 labeled with (177)Lu has been used in clinical trials for radioimmunotherapy (RIT) of RCCs. In this work, an extensive characterization of the immunoconjuga...

Descripción completa

Detalles Bibliográficos
Autores principales: Basaco, Tais, Pektor, Stefanie, Bermudez, Josue M., Meneses, Niurka, Heller, Manfred, Galván, José A., Boligán, Kayluz F., Schürch, Stefan, von Gunten, Stephan, Türler, Andreas, Miederer, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6316122/
https://www.ncbi.nlm.nih.gov/pubmed/30487460
http://dx.doi.org/10.3390/ph11040132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6316122/
https://www.ncbi.nlm.nih.gov/pubmed/30487460
http://dx.doi.org/10.3390/ph11040132

Ejemplares similares